AR068814A1 - Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso - Google Patents
Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y usoInfo
- Publication number
- AR068814A1 AR068814A1 ARP080103754A ARP080103754A AR068814A1 AR 068814 A1 AR068814 A1 AR 068814A1 AR P080103754 A ARP080103754 A AR P080103754A AR P080103754 A ARP080103754 A AR P080103754A AR 068814 A1 AR068814 A1 AR 068814A1
- Authority
- AR
- Argentina
- Prior art keywords
- angiotensin
- ace
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinacion de un compuesto de levosimendán o una sal farmacéuticamente aceptable del mismo y un antagonista receptor de angiotensina II o un inhibidor de enzima conversiva de la angiotensina (ACE) muestra un efecto sinergístico en la prevencion de apoplejía. Se proporcionan composiciones farmacéuticas y equipos médicos que comprenden como un primer ingrediente activo un compuesto de levosimendán o una sal farmacéuticamente aceptable del mismo y como un segundo ingrediente activo un antagonista receptor de angiotensina II o un inhibidor de enzima conversiva de la angiotensina (ACE). Reivindicacion 2: La composicion de conformidad con la reivindicacion 1, caracterizada porque el antagonista receptor de angiotensina II es losartán, valsartán, telmisartán, candesartán, eprosartán, irbesartán, olmesartán, tasosartán o una sal farmacéuticamente aceptable de los mismos. Reivindicacion 3: La composicion de conformidad con la reivindicacion 1, caracterizada porque el inhibidor de enzima conversiva de la angiotensina (ACE) es ramipril, captopril, enalapril, quinapril, perindopril, lisinopril, benazepril, moexipril, trandolapril o una sal farmacéuticamente aceptable de lo mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96858307P | 2007-08-29 | 2007-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068814A1 true AR068814A1 (es) | 2009-12-09 |
Family
ID=40043957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103754A AR068814A1 (es) | 2007-08-29 | 2008-08-28 | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100249103A1 (es) |
| EP (1) | EP2185141A1 (es) |
| AR (1) | AR068814A1 (es) |
| CA (1) | CA2695822A1 (es) |
| CL (1) | CL2008002555A1 (es) |
| PE (1) | PE20090675A1 (es) |
| TW (1) | TW200920371A (es) |
| WO (1) | WO2009027577A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027021A1 (en) | 2009-09-01 | 2011-03-10 | Orion Corporation | A method for the treatment of hypertension |
| CN106214680B (zh) * | 2016-07-29 | 2018-05-11 | 珠海赛隆药业股份有限公司（长沙）医药研发中心 | 一种血管紧张素受体拮抗剂和左西孟旦的复合物及其用途 |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020260A2 (en) * | 1997-10-17 | 1999-04-29 | Eurogene Limited | The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| US5905078A (en) | 1998-06-19 | 1999-05-18 | Orion Corporation | Use of a pyridazinone derivative |
| TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
| FI20040674A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
| EP1908469A1 (en) * | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
-
2008
- 2008-08-28 AR ARP080103754A patent/AR068814A1/es not_active Application Discontinuation
- 2008-08-28 TW TW097132861A patent/TW200920371A/zh unknown
- 2008-08-29 PE PE2008001464A patent/PE20090675A1/es not_active Application Discontinuation
- 2008-08-29 EP EP08805411A patent/EP2185141A1/en not_active Withdrawn
- 2008-08-29 US US12/674,689 patent/US20100249103A1/en not_active Abandoned
- 2008-08-29 CL CL2008002555A patent/CL2008002555A1/es unknown
- 2008-08-29 CA CA2695822A patent/CA2695822A1/en not_active Abandoned
- 2008-08-29 WO PCT/FI2008/000097 patent/WO2009027577A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA2695822A1 (en) | 2009-03-05 |
| WO2009027577A1 (en) | 2009-03-05 |
| TW200920371A (en) | 2009-05-16 |
| PE20090675A1 (es) | 2009-06-13 |
| US20100249103A1 (en) | 2010-09-30 |
| CL2008002555A1 (es) | 2009-04-03 |
| EP2185141A1 (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507244A5 (es) | ||
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| PE20020229A1 (es) | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE | |
| GT200900328A (es) | Derivados de bencimidazol | |
| CY1106813T1 (el) | Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης | |
| NO20063997L (no) | Tablett med flere lag | |
| CL2011002180A1 (es) | Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor. | |
| CL2013000351A1 (es) | Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias. | |
| PE20070803A1 (es) | Combinacion farmaceutica de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra | |
| AR063155A1 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
| PE20061195A1 (es) | Derivado de bencimidazol como antagonista de angiotensina ii | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| JP2003521437A5 (es) | ||
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| PE20121131A1 (es) | Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina | |
| AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso | |
| JP2003238444A (ja) | アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物 | |
| EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
| RU2016126852A (ru) | Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| WO2010097501A3 (en) | A combination treatment of stroke | |
| AR080256A1 (es) | Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion | |
| TR201004754A1 (tr) | Yeni Farmasötik Kombinasyonlar | |
| TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
| AR081376A1 (es) | Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |